PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
Malaysia rolled out a diverse portfolio of predominantly three COVID-19 vaccines (AZD1222, BNT162b2, and CoronaVac) beginning 24 February 2021. We evaluated vaccine effectiveness with two methods, covering 1 April to 15 September 2021: (1) the screening method for COVID-19 (SARS-CoV-2) infection and...
Main Authors: | Jing Lian Suah, Peter Seah Keng Tok, Su Miin Ong, Masliyana Husin, Boon Hwa Tng, Sheamini Sivasampu, Thevesh Thevananthan, Maheshwara Rao Appannan, Faizah Muhamad Zin, Shahanizan Mohd Zin, Hazlina Yahaya, Norhayati Rusli, Mohd Fikri Ujang, Hishamshah Mohd Ibrahim, Noor Hisham Abdullah, Kalaiarasu M. Peariasamy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/12/1381 |
Similar Items
-
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
by: Jing Lian Suah, et al.
Published: (2022-06-01) -
Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
by: Jing Lian Suah, et al.
Published: (2022-12-01) -
Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
by: Masliyana Husin, et al.
Published: (2022-08-01) -
Effectiveness of COVID-19 vaccines among children 6–11 years against hospitalization during Omicron predominance in Malaysia
by: Vivek Jason Jayaraj, et al.
Published: (2024-03-01) -
Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study
by: Ee Vien Low, et al.
Published: (2023-10-01)